Aug 5, 2022 7:00am EDT Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022
Jun 8, 2022 7:00am EDT Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022